Celularity Inc.
CELUAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 23, 2022 | Truist Financial | Asthika Goonewardene | $6.00(+329%) | $1.40 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| WBB Securities | upgrade | Hold →Buy | Sep 9, 2025 |
| Morgan Stanley | downgrade | Equal Weight →Underweight | Jan 29, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jan 29, 2023 |
| Oppenheimer | downgrade | Outperform →Perform | Dec 21, 2022 |
| Morgan Stanley | maintain | Equal Weight | Sep 11, 2022 |
| Alliance Global Partners | maintain | Buy | Aug 25, 2022 |
| Truist Securities | maintain | Hold | Aug 22, 2022 |
| HC Wainwright & Co. | maintain | Buy | Jun 22, 2022 |
| Truist Securities | downgrade | Buy →Hold | Apr 5, 2022 |
| Oppenheimer | maintain | Outperform | Jan 28, 2022 |
| Morgan Stanley | maintain | Equal Weight | Nov 24, 2021 |
| Truist Securities | maintain | Buy | Oct 19, 2021 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 20, 2026 | $-0.12 | — | — | — |
| Sep 29, 2026 | $0.02 | — | $5.4M | — |
| Apr 30, 2026 | $-0.95 | $-1.50 | $4.1M | $4.1M |
| Nov 14, 2025 | $-0.88 | $-1.50 | $5.3M | $5.3M |
| Aug 29, 2025 | $-0.75 | — | $5.7M | — |
| May 8, 2025 | $-0.84 | $-1.50 | $11.4M | $5.2M |
| Dec 6, 2024 | $-0.73 | $-1.40 | $9.3M | $5.3M |
| Nov 7, 2024 | $-0.30 | $-1.40 | $12.1M | $4.8M |
News
FLORHAM PARK, N.J. & SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and Vesalius Longevity Labs Inc. (“Vesalius”), a leading, global peptide and longevity brand, today announced that they have entered into an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind, U.S. final stage API manufacturing and supply platform for Vesalius's Peptual-branded active pharmaceutical ing.
FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced that it received written confirmation from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission.
Celularity highlights Fontaine Vitale's planned Q1 2027 opening in Bali, creating potential new revenue opportunities in Asia-Pacific regenerative medicine
FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company, today announced that Naveen Jain, founder and Chief Executive Officer of Viome Life Sciences Inc. (“Viome”), will join its Board of Directors.
Celularity closes $10 million financing in an up to $28 million recapitalization, advancing growth and targeting positive operating cash flow by Q1 2027.
[url="]Celularity Inc.[/url] (Nasdaq: CELU) (âCelularityâ), a longevity-focused regenerative and cellular medicine company, and [url="]MuseCell InnovationsÂ
FLORHAM PARK, N.J. & SINGAPORE--(BUSINESS WIRE)--Celularity Inc. and MuseCell Innovations announce U.S. manufacturing partnership for production of Dezawa MuseCells in Florham Park, NJ facility.
FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compli…